Marker Therapeutics (MRKR) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $17.6 million.
- Marker Therapeutics' Cash & Equivalents rose 9545.15% to $17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.6 million, marking a year-over-year increase of 9545.15%. This contributed to the annual value of $19.2 million for FY2024, which is 2705.6% up from last year.
- According to the latest figures from Q3 2025, Marker Therapeutics' Cash & Equivalents is $17.6 million, which was up 9545.15% from $10.5 million recorded in Q2 2025.
- Over the past 5 years, Marker Therapeutics' Cash & Equivalents peaked at $64.5 million during Q1 2021, and registered a low of $6.4 million during Q1 2023.
- Its 5-year average for Cash & Equivalents is $23.3 million, with a median of $17.6 million in 2025.
- Per our database at Business Quant, Marker Therapeutics' Cash & Equivalents soared by 9834.39% in 2021 and then plummeted by 7764.71% in 2023.
- Marker Therapeutics' Cash & Equivalents (Quarter) stood at $42.4 million in 2021, then plummeted by 72.18% to $11.8 million in 2022, then grew by 28.26% to $15.1 million in 2023, then increased by 27.06% to $19.2 million in 2024, then fell by 8.39% to $17.6 million in 2025.
- Its Cash & Equivalents was $17.6 million in Q3 2025, compared to $10.5 million in Q2 2025 and $13.7 million in Q1 2025.